# US Animal Model Market > US Animal Model Market Research Report: Size, Share, Trend Analysis By Animal Type (Pigs, Cats, Mice), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection), By Applications (Research & Development, Production, Quality Control) and By End-User (Research Institutes, Educational Institutes, Pharmaceutical Companies, Contract Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.12% - **2024:** $ 444.47 Million - **2025:** $ 476.12 Million - **2035:** $ 947.17 Million - **Key Players:** Charles River Laboratories (US), Envigo (US), Taconic Biosciences (US), Harlan Laboratories (US), Laboratory Corporation of America Holdings (US), Wuxi AppTec (CN), Crown Bioscience (US), Inotiv (US) **Report ID:** MRFR/Pharma/15206-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-animal-model-market-16734 --- ## Market Summary ## **US Animal Model Market Overview** As per MRFR analysis, the US Animal Model Market Size was estimated at 726.66 (USD Million) in 2023. The US Animal Model Market Industry is expected to grow from 778.4(USD Million) in 2024 to 1,487.2 (USD Million) by 2035. The US Animal Model Market CAGR (growth rate) is expected to be around 6.062% during the forecast period (2025 - 2035). ### **Key US Animal Model Market Trends Highlighted** The US Animal Model Market is currently shaped by several significant trends that reflect the evolving needs of research and development. One of the key market drivers is the rising demand for advanced therapeutic solutions, particularly in areas such as oncology, immunology, and neurology. The increasing complexity of human diseases necessitates the use of animal models to gain a deeper understanding of disease mechanisms and test potential treatments effectively. Regulatory bodies, including the Food and Drug Administration (FDA), are emphasizing the importance of animal models in the drug development process, further driving the demand in this market. Opportunities to be captured within the US Animal Model Market include the growing interest in personalized medicine and targeted therapies. Companies are focusing on developing genetically modified animal models that can simulate specific human diseases more accurately. This trend not only enhances the relevance of preclinical studies but also leads to improved success rates in clinical trials. Collaborations between academic institutions and pharmaceutical companies are expected to foster innovation, paving the way for new model developments that can address specific research challenges. Recent times have also seen a shift towards the ethical use of animal models, influenced by public sentiment and regulatory changes. There is a greater emphasis on the 3Rs principle—Replacement, Reduction, and Refinement—advocating for humane practices in research. This shift is prompting researchers to seek alternatives and minimizing the number of animals used while enhancing their welfare. Moreover, advancements in technology, such as 3D bioprinting and artificial intelligence, are increasingly integrated into the traditional animal research framework, creating exciting avenues for future exploration in human health. Overall, the landscape is dynamic and evolving, reflecting a blend of scientific advancement and ethical considerations in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Animal Model Market Drivers** ### **Increasing Prevalence of Chronic Diseases** The rise in chronic diseases such as cancer, diabetes, and cardiovascular diseases in the United States significantly drives the US Animal Model Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 6 in 10 Americans have a chronic disease, with cancer rates accounting for about 1.8 million new cases annually. This alarming statistic highlights the urgent need for research to develop effective treatments and therapies, driving demand for animal models in Research and Development (R&D) processes. Organizations like the American Cancer Society and the National Institutes of Health have been pivotal in backing extensive research, ultimately leading to enhanced funding and resources directed toward studies involving animal models. Consequently, the heightened focus on chronic diseases results in an expanded application of animal models in clinical research settings, fostering growth in the US Animal Model Market Industry. ### **Advancements in Biotechnology** Innovations in biotechnology are rapidly evolving, contributing significantly to the growth of the US Animal Model Market Industry. The National Institutes of Health reports that biotechnology firms have seen substantial investments, surpassing $74 billion, catalyzing advancements related to genetic engineering and tailored therapies. This surge in budget allocations towards biotechnology-based research creates a robust demand for animal models, essential for understanding biological processes and testing new drug candidates. As companies such as Amgen and Genentech lead in biopharmaceutical innovation, the focus on utilizing animal models for preclinical testing enhances the industry's growth trajectory in the U.S. ### **Rising Investment in Pharmaceutical Research** The United States remains a leading hub for pharmaceutical research and development, with expenditures exceeding $90 billion annually. This significant investment trend positively influences the US Animal Model Market Industry as pharmaceutical companies increasingly rely on animal models to ensure drug safety and efficacy. The Biophysical Society highlights that approximately 75% of new drug candidates undergo animal testing before they reach clinical trials. Moreover, major pharmaceutical companies like Pfizer and Johnson & Johnson leverage animal models to advance their Research and Development processes, thereby propelling market growth. The continuous push for innovation in drug development further stimulates the need for diverse animal models, ultimately benefiting the market. ### **Regulatory Support for Animal Models** The regulatory landscape in the United States supports the use of animal models in research, which is vital for the US Animal Model Market Industry. Agencies such as the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) mandate preclinical testing on animal models to ensure the safety of drugs and chemicals before they reach humans. This regulatory requirement for comprehensive testing provides a solid framework that encourages the use of animal models in research and product development. Additionally, the National Research Council's emphasis on the 3Rs principle (Replacement, Reduction, Refinement) facilitates ethical frameworks coupled with significant investments in animal welfare, thus promoting animal models' acceptance and usage in advancing biomedical research. Such support from regulatory bodies creates a positive outlook for the market's growth. ## **US Animal Model Market Segment Insights** ### **Animal Model Market Animal Type Insights** The US[**Animal Model Market**](../../../reports/animal-model-market-9709)encompasses various animal types that are instrumental for research, drug development, and various scientific investigations. Among these, animals such as pigs, cats, and mice play a crucial role due to their unique biological traits and similarities to human physiology. The increasing complexity of disease modeling and the support from regulatory bodies in the US further underline the necessity of these animal types in the scientific community. Trends in biomedicine, including personalized medicine and advanced therapeutic modalities, emphasize the reliance on these animals for the exploration and validation of innovative treatment options. Growth drivers in the US market revolve around the rising funding for research initiatives and the growing synergy between academic institutions and industry that aim to translate scientific discoveries into real-world applications. Challenges related to ethical considerations and increasing regulations surrounding animal welfare persist, but they simultaneously drive the development of alternative methods and technologies that could enhance research outcomes. Overall, the various animal types within the US Animal Model Market are pivotal in supporting research and development initiatives, impacting both human health and the advancement of veterinary practices. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Animal Model Market Technology Insights** The Technology segment of the US Animal Model Market plays a crucial role in enhancing research capabilities and advancing scientific discoveries. CRISPR technology has gained significant traction due to its precise genome-editing capabilities, allowing for efficient genetic manipulation that is vital for research in various fields, including genetics and disease modeling. The growth of these technologies is driven by increasing investments in Research and Development initiatives, demand for personalized medicine, and a rising focus on ethical research practices. However, the market also faces challenges such as regulatory hurdles and ethical considerations surrounding animal testing, which can impact the adoption of these advanced technologies. Overall, the dynamic landscape within this technology segment supports innovation and contributes significantly to the US Animal Model Market statistics and data trends. ### **Animal Model Market Application Insights** The US Animal Model Market is experiencing notable growth, driven by applications in Research and Development, Production, and Quality Control. The importance of these applications cannot be understated, as they support various industries, including pharmaceuticals and biotechnology, in developing innovative therapies and testing products. As regulatory standards evolve and the demand for more sophisticated models increases, the segmentation within the US Animal Model Market is expected to adapt accordingly. Furthermore, the ongoing emphasis on ethical considerations in animal research will likely influence how these applications are implemented, promoting a more humane approach while maintaining scientific rigor. Overall, the Application segment in the US Animal Model Market represents a vital foundation for advancement in healthcare and science. ### **Animal Model Market End-User Insights** The End-User segment of the US Animal Model Market encompasses various key players including Research Institutes, Educational Institutes, Pharmaceutical Companies, and Contract Research Organizations. Research Institutes are essential for conducting advanced studies and developing new therapies, thereby driving significant contributions to overall market dynamics. The collaborative efforts among these various entities enhance innovation and accelerate market development, driven by growing R&D investments within the US which further solidify the significance of these End-Users in the overall landscape of the US Animal Model Market. This segment reflects the ongoing trends in biomedical research and emphasizes the critical role of animal models in achieving groundbreaking medical advancements. ## **US Animal Model Market Key Players and Competitive Insights** The US Animal Model Market is a vital segment within the broader life sciences industry, focusing on the development and distribution of animal models used for research and development in pharmaceuticals, biotechnology, and academic institutions. Competitive dynamics within this market are characterized by a mix of established players and emerging firms, each striving to enhance their offerings through innovative breeding, genetics, and customization of animal models to meet specific research requirements. The industry's growth is significantly influenced by advancements in genetic engineering and an increasing demand for reliable preclinical models for drug testing and disease studies. Companies are continuously pursuing strategies such as partnerships, collaborations, and mergers to expand their market presence and enhance their product portfolios, which contributes to a dynamic and competitive landscape. Taconic Biosciences is a key player in the US Animal Model Market, known for its extensive range of genetically engineered models that cater to various research needs. The company boasts significant strengths in its ability to produce custom models, which allows researchers to have tailored solutions for their specific projects. Taconic's robust infrastructure and high-quality animal husbandry practices ensure that their models are reliable for preclinical research. The company has established a strong foothold in the market by leveraging its extensive experience in the field and maintaining rigorous quality control measures. Additionally, Taconic's commitment to innovation and customer service has enhanced its reputation as a trusted provider, enabling it to forge long-lasting relationships with academic and industry partners across the United States. SABC is another prominent player within the US Animal Model Market, offering a wide array of animal models for research purposes. The company focuses on providing genetically modified organisms, which are crucial in various research sectors, including cancer, metabolic disorders, and immunology. SABC's strengths lie in its comprehensive product portfolio alongside advanced research capabilities that facilitate custom breeding and development of unique animal models. The company has also expanded its market presence through strategic mergers and acquisitions, enhancing its research capabilities and geographic reach. With ongoing investments in technology and infrastructure, SABC is well-positioned to meet the evolving needs of researchers and continues to solidify its role as a leader in the US animal model market. Its focus on high-quality service and innovative solutions distinguishes SABC from competitors, making it a valuable partner in the research community. ### **Key Companies in the US Animal Model Market Include** ## **US Animal Model Market Industry Developments** The US Animal Model Market has recently witnessed several significant developments. In September 2023, Charles River Laboratories announced the acquisition of the global mouse model company, expanding its portfolio to enhance its research capabilities in preclinical models. This acquisition aligns with the increasing demand for advanced models in drug discovery. In October 2023, Taconic Biosciences launched a new genetically engineered mouse model to support Research and Development in cancer therapy, catering to the growing needs of the biomedical research community. Additionally, Eurofins Scientific has been investing in expanding its animal model services, emphasizing improved welfare standards and compliance with regulatory requirements. The market valuation for companies such as Jackson Laboratory and Envigo has seen substantial growth, attributed to the escalating focus on precision medicine and personalized healthcare. Furthermore, in April 2022, Bolder BioTechnology secured a new funding round to advance its capabilities in animal model development, signaling a positive investment climate. Overall, the US Animal Model Market is experiencing a surge in technological advancements, strategic acquisitions, and a heightened emphasis on ethical practices, all contributing to its dynamic growth and evolution. ## **US Animal Model Market Segmentation Insights** ### **Animal Model Market Animal Type Outlook** ### **Animal Model Market Technology Outlook** ### **Animal Model Market Application Outlook** ### **Animal Model Market End-User Outlook** ## Market Drivers ### Advancements in Genetic Engineering Advancements in genetic engineering techniques, such as CRISPR, are transforming the landscape of the animal model market. These technologies enable the creation of genetically modified animals that can serve as precise models for human diseases. The ability to tailor animal models to specific genetic profiles enhances their relevance in research. The animal model market is poised to benefit from these innovations, as researchers increasingly seek models that can accurately reflect human genetic diversity. This trend may lead to more effective drug development and personalized treatment strategies, further driving the market's growth. ### Growing Focus on Disease Understanding The increasing emphasis on understanding complex diseases is propelling the animal model market forward. As researchers strive to unravel the mechanisms behind diseases such as cancer, diabetes, and neurodegenerative disorders, the demand for relevant animal models is expected to rise. The animal model market is crucial in providing models that can mimic these conditions, facilitating deeper insights into disease pathology. This focus on disease understanding is likely to drive innovation in model development, ensuring that researchers have access to the most effective tools for their studies. ### Expansion of Biopharmaceutical Research The biopharmaceutical sector is experiencing rapid growth, which is positively impacting the animal model market. With the biopharmaceutical market expected to surpass $500 billion by 2025, the demand for animal models that can aid in drug discovery and development is likely to increase. These models are essential for preclinical testing, allowing researchers to evaluate the efficacy and safety of new drugs before human trials. The animal model market plays a crucial role in this process, as it provides the necessary tools for biopharmaceutical companies to innovate and bring new therapies to market efficiently. ### Rising Demand for Personalized Medicine The increasing focus on personalized medicine is driving growth in the animal model market. As healthcare shifts towards tailored treatments, the need for specific animal models that can accurately mimic human diseases becomes paramount. This trend is evident in the pharmaceutical sector, where companies are investing heavily in research and development. In 2025, the market for personalized medicine is projected to reach approximately $350 billion in the US, indicating a robust demand for animal models that can facilitate this research. The animal model market is thus positioned to benefit significantly from this shift, as researchers require models that can provide insights into individual responses to therapies. ### Increased Investment in Research and Development Investment in research and development (R&D) is a key driver of the animal model market. In the US, R&D spending in the life sciences sector is projected to reach $200 billion by 2025. This surge in funding is likely to enhance the development of advanced animal models that can better replicate human diseases. The animal model market stands to gain from this trend, as researchers seek more sophisticated models to improve the accuracy of their studies. Enhanced R&D efforts may lead to breakthroughs in various therapeutic areas, further solidifying the importance of animal models in scientific research. ## Future Outlook The [Animal Model Market](https://www.marketresearchfuture.com/reports/animal-model-market-9709) is projected to grow at a 7.12% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing R&D investments, and regulatory support. **New opportunities:** - Development of genetically modified animal models for precision medicine applications. Expansion of contract research organizations (CROs) offering specialized animal model services. Integration of AI technologies for enhanced data analysis in animal studies. By 2035, the animal model market is expected to achieve substantial growth, reflecting evolving research needs and technological advancements. ## Segment Insights ### By Animal Type: Pigs (Largest) vs. Mice (Fastest-Growing) In the US animal model market, the distribution of market share among various animal types showcases pigs as the largest segment. Their established use in various research applications contributes significantly to their market dominance. In contrast, mice have been rapidly gaining popularity due to their prevalence in research settings, thus capturing a substantial and growing share of the market. The strategic use of smaller animal models in laboratories is fostering this shift. Growth trends in this segment are driven by the increasing demand for more cost-effective and ethical research models. The robust pipeline for drug discovery along with technological advancements in genetic engineering are bolstering the use of both pigs and mice. With a focus on regulatory compliance and animal welfare, research facilities are leaning more towards these animals for diverse research and testing applications, ensuring their relevance in the evolving landscape. Pigs (Dominant) vs. Mice (Emerging) Pigs are a dominant force in the animal model market largely due to their physiological similarities to humans, which make them invaluable in preclinical studies, particularly in fields such as cardiology and diabetes research. Their size and organ function closely mirror human counterparts, allowing for more predictive translational outcomes. Conversely, mice represent an emerging segment, favored for their genetic manipulability and shorter life cycles which enable rapid testing processes. With advancements in immunology and oncology research, the versatility of mice as model organisms continues to expand, driving their increased adoption in laboratories. This dual reliance on pigs and mice reflects a well-rounded approach to fulfilling diverse research needs in order to improve therapeutic outcomes. ### By Technology: CRISPR (Largest) vs. Microinjection (Fastest-Growing) In the US animal model market, CRISPR technology holds the largest market share, significantly outpacing other methods. Microinjection and embryonic stem cell injection follow, with microinjection experiencing notable adoption due to its precision and efficiency in creating genetically modified models. Overall, this segment is characterized by a variety of technologies contributing to diverse applications in research and product development. Growth trends indicate a robust expansion for CRISPR driven by increased investment in genetic research and biotechnology. The rising demand for advanced animal models to study human diseases and test new therapies fuels the adoption of these technologies. Moreover, innovations in microinjection techniques enhance their attractiveness, making them the fastest-growing method in the segment, supported by ongoing research initiatives and funding in biomedical and agricultural applications. Technology: CRISPR (Dominant) vs. Microinjection (Emerging) CRISPR technology stands out as the dominant force in the market due to its revolutionary gene-editing capabilities, enabling precise modifications at a low cost. This has resulted in wide adoption across various therapeutic and research applications. In contrast, microinjection, although an emerging method, is rapidly gaining traction for its ability to introduce foreign DNA into embryos, thereby creating genetically modified organisms. The efficiency of microinjection is enhanced by technological advancements, making it an attractive choice for researchers focused on developmental biology. Both technologies exhibit unique strengths, with CRISPR leading in widespread acceptance and microinjection poised for continual growth. ### By Application: Research and Development (Largest) vs. Quality Control (Fastest-Growing) In the US animal model market, the application segment is primarily dominated by the Research and Development category, accounting for a significant share of market activities. Alternatively, the Quality Control segment is rapidly gaining traction, driven by the increasing need for regulatory compliance and product safety in animal testing. The Production segment, while essential, holds a smaller share relative to these two key areas. Growth trends in the application segment are influenced by several factors, including technological advancements and an increasing emphasis on ethical practices in research. The demand for more efficient and humane testing methodologies is steering investment towards Quality Control. At the same time, Research and Development remains robust as pharmaceutical and biotechnology companies strive to innovate and bring new treatments to market, thereby solidifying its position as the largest segment. Research and Development (Dominant) vs. Quality Control (Emerging) The Research and Development segment is characterized by its pivotal role in the discovery of new drugs and therapies, often requiring extensive testing on various animal models to assess efficacy and safety. This segment has established precedence due to its foundational importance in advancing medical science. On the other hand, the Quality Control segment is an emerging powerhouse, reflecting the growing recognition of the necessity for stringent testing protocols that ensure consistency and compliance with regulatory standards. Together, these segments illustrate a dynamic landscape in the US animal model market, where innovation drives R&D while quality assurance efforts are poised to expand rapidly. ### By End User: Pharmaceutical Companies (Largest) vs. Research Institutes (Fastest-Growing) The market share distribution among the segment values in the animal model market showcases that Pharmaceutical Companies hold the largest share, driven by their extensive need for preclinical testing and drug development. This segment benefits from significant investments in research and development, establishing a stronghold in the sector. Research Institutes, while smaller in market share, are emerging rapidly due to a growing emphasis on academic research and collaboration with industry stakeholders, marking them as a vital component of the market landscape. Growth trends indicate that the demand from Pharmaceutical Companies will continue to drive the market, leveraging advancements in biotechnology and pharmaceutical innovations. Meanwhile, Research Institutes are experiencing an upward trajectory fueled by increased funding and partnerships, enhancing their capability to contribute to key research initiatives. The expansion of Contract Research Organizations is also notable, as they bridge the gap between academic research and commercial applications, ensuring a steady incline in market dynamics. Pharmaceutical Companies (Dominant) vs. Research Institutes (Emerging) Pharmaceutical Companies remain the dominant force in the US animal model market, characterized by their robust infrastructure and commitment to innovation. These companies engage extensively in drug discovery processes that necessitate the use of animal models, ensuring effective preclinical testing. Conversely, Research Institutes are emerging as pivotal players, driven by collaborative research projects and increased funding from government and private sectors. This segment emphasizes fundamental research and education, which is transforming the landscape of animal model usage. As the industry evolves, both segments showcase unique strengths; the former focuses on commercial viability while the latter promotes scientific advancement and knowledge dissemination. ## Competitive Benchmarking The animal model market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations among key players. Major companies such as Charles River Laboratories (US), Envigo (US), and Taconic Biosciences (US) are at the forefront, leveraging their extensive portfolios and expertise to drive growth. Charles River Laboratories (US) focuses on enhancing its service offerings through technological advancements, while Envigo (US) emphasizes sustainability in its operations. Taconic Biosciences (US) is strategically positioned to expand its global footprint, indicating a trend towards regional diversification that shapes the competitive environment. Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The competitive structure appears moderately fragmented, with several players vying for market share. However, the collective influence of these key players fosters a collaborative atmosphere, where partnerships and alliances are increasingly common, thereby enhancing the overall market dynamics. In September 2025, Charles River Laboratories (US) announced a strategic partnership with a leading biotechnology firm to develop advanced animal models for preclinical research. This collaboration is likely to enhance their product offerings and strengthen their position in the market, as it aligns with the growing demand for innovative solutions in drug development. The partnership underscores the importance of collaboration in driving technological advancements and meeting client needs. In August 2025, Envigo (US) launched a new line of genetically modified animal models aimed at accelerating research in personalized medicine. This initiative not only reflects the company's commitment to innovation but also positions it to capture a larger share of the market focused on precision medicine. The introduction of these models may significantly enhance research capabilities for pharmaceutical companies, thereby reinforcing Envigo's competitive edge. In October 2025, Taconic Biosciences (US) expanded its operations by opening a new facility dedicated to the production of high-quality animal models. This expansion is indicative of the company's strategy to meet the increasing demand for animal models in various research sectors. By enhancing its production capabilities, Taconic is likely to improve its service delivery and responsiveness to market needs, further solidifying its market position. As of November 2025, current trends in the animal model market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to foster innovation. The competitive differentiation is expected to evolve, shifting from price-based competition to a focus on technological advancements, supply chain reliability, and innovative solutions that meet the evolving demands of the research community. ## Recent News & Developments The US Animal Model Market has recently witnessed several significant developments. In September 2023, Charles River Laboratories announced the acquisition of the global mouse model company, expanding its portfolio to enhance its research capabilities in preclinical models. This acquisition aligns with the increasing demand for advanced models in drug discovery. In October 2023, Taconic Biosciences launched a new genetically engineered mouse model to support Research and Development in cancer therapy, catering to the growing needs of the biomedical research community. Additionally, Eurofins Scientific has been investing in expanding its animal model services, emphasizing improved welfare standards and compliance with regulatory requirements. The market valuation for companies such as Jackson Laboratory and Envigo has seen substantial growth, attributed to the escalating focus on precision medicine and personalized healthcare. Furthermore, in April 2022, Bolder BioTechnology secured a new funding round to advance its capabilities in animal model development, signaling a positive investment climate. Overall, the US Animal Model Market is experiencing a surge in technological advancements, strategic acquisitions, and a heightened emphasis on ethical practices, all contributing to its dynamic growth and evolution. ## Report Scope | MARKET SIZE 2024 | 444.47(USD Million) | | --- | --- | | MARKET SIZE 2025 | 476.12(USD Million) | | MARKET SIZE 2035 | 947.17(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.12% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Charles River Laboratories (US), Envigo (US), Taconic Biosciences (US), Harlan Laboratories (US), Laboratory Corporation of America Holdings (US), Wuxi AppTec (CN), Crown Bioscience (US), Inotiv (US) | | Segments Covered | Animal Type, Technology, Application, End User | | Key Market Opportunities | Advancements in genetic engineering enhance precision in the animal model market for biomedical research. | | Key Market Dynamics | Rising demand for advanced animal models drives innovation and regulatory scrutiny in preclinical research. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US animal model market?** A: The market valuation was $444.47 Million in 2024. **Q: What is the projected market size for the US animal model market by 2035?** A: The market is projected to reach $947.17 Million by 2035. **Q: What is the expected CAGR for the US animal model market during the forecast period 2025 - 2035?** A: The expected CAGR is 7.12% during the forecast period. **Q: Which animal types contribute significantly to the US animal model market?** A: Mice, with a valuation range of $264.47 Million to $587.17 Million, are a major contributor. **Q: What technologies are driving growth in the US animal model market?** A: CRISPR technology is projected to grow from $100 Million to $250 Million. **Q: What are the primary applications of animal models in the US market?** A: Research and Development applications accounted for $177.78 Million to $377 Million. **Q: Who are the key players in the US animal model market?** A: Key players include Charles River Laboratories, Envigo, and Taconic Biosciences. **Q: What role do pharmaceutical companies play in the US animal model market?** A: Pharmaceutical companies are projected to contribute $222.23 Million to $469.45 Million. **Q: How do educational institutes impact the US animal model market?** A: Educational institutes are expected to account for $44.45 Million to $95.12 Million. **Q: What is the significance of contract research organizations in the US animal model market?** A: Contract research organizations are projected to generate $110.9 Million to $239.48 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-animal-model-market-16734*